Nasus Pharma Ltd announced on February 10, 2026, a private placement financing to institutional investors, raising $15 million by selling 2,695,425 ordinary shares at $5.565 each, along with warrants. The funds are earmarked for advancing clinical development of their products and general corporate purposes.